ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

[Construction of recombinant adenovirus carrying human IFNgamma gene by in vitro ligation and its expression].

BACKGROUND & OBJECTIVE: Interferon-gamma (IFNgamma) can promote directly the apoptosis of some kinds of tumor cells and regulate cellular immunity, therefore, it may play an important role in gene therapy for tumors. This study was to construct recombinant adenovirus carrying human IFNgamma cDNA, and detect its expression profile in eukaryotic cells.

METHODS: IFNgamma cDNA was amplified by reverse transcription-polymerase chain reaction (RT-PCR) from human peripheral blood mononuclear cells, and cloned into adenoviral shuttle plasmid pShuttle to construct recombinant adenovirus carrying human IFNgamma cDNA (Ad-IFNgamma) by in vitro ligation. Hepatocellular carcinoma cell line HepG2 was infected with Ad-IFNgamma, and the expression of IFNgamma was detected by RT-PCR and immunohistochemistry.

RESULTS: The sequence of the cloned IFNgamma cDNA was completely consistent with that reported in GenBank. PCR analysis confirmed the existence of IFNgamma gene in Ad-IFNgamma without wild adenovirus contamination, and the genome of Ad-IFNgamma showed the predicted map of restricted endonuclease enzymes analysis. IFNgamma mRNA and protein were detected in HepG2 cells infected with Ad-IFNgamma.

CONCLUSIONS: In vitro ligation is a simple and convenient method for construction of recombination adenovirus vector. We have constructed a functional recombinant adenovirus expressing human IFNgamma, which could be a potential antivirus and antitumor agent in vitro or in vivo.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app